Clinical trials: Chronic Obstructive Pulmonary Disease Severe
Chronic Obstructive Pulmonary Disease
Effects on PaCO2 Levels of Two Different Nasal Cannula in COPD Patients
High-flow nasal cannula (HFNC) therapy is increasingly used in the management of acute respiratory failure. Its clinical application has been expanded also in other specific settings In stable COPD patients and in those…
- Trial name
- CODUET (NCT05528289)
- Testing
- AIRVO 2, with conventional symmetric nasal cannula, AIRVO 2, the new asymmetric nasal cannula
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
- Trial name
- CODEX (NCT00489853)
- Testing
- budesonide/formoterol Turbuhaler 320/9µg, formoterol Turbuhaler 9µg
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007).
- Trial name
- NCT01970878
- Testing
- GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005)
- Where
- 125 sites in United States, Australia and 1 more
- Volunteers
- 892 people
- Sponsor
- Pearl Therapeutics, Inc.
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
- Trial name
- Sirius (NCT07646587)
- Testing
- WIN378
- Where
- 32 sites in United States, Argentina
- Volunteers
- 105 people
- Sponsor
- Windward Bio
Lung Diseases, Obstructive, Postoperative Complications
Preoperative Diagnostic Tests for Pulmonary Risk Assessment in COPD
This prospective study intends to investigate the incidence of postoperative pulmonary complications (PPC) or in-hospital mortality in patients with COPD or at risk for COPD undergoing high-risk noncardiac major surgery and to…
- Trial name
- PredicT (NCT02566343)
- Where
- Germany
- Volunteers
- 365 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition that results in a mixture of small airway disease and parenchymal destruction, changes that are characteristic of emphysema.
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe, Acute Exacerbation of COPD
- Trial name
- NMES (NCT05539547)
- Testing
- Neuromuscular Electrical Nerve Stimulation, Usual Physiotherapy treatment (Chest Physiotherapy and mobility)
- Volunteers
- 140 people
- Sponsor
- Randall Debattista
Chronic Obstructive Pulmonary Disease
A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the influence of exercise capacity and safety of iNO at doses of 10 ppm or 40 ppm for 2 hours per day after continuous treatment for one week, which is of great significance for finding…
- Trial name
- NOVEL (NCT05896800)
- Testing
- Inhaled nitric oxide (NO), air
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Emphysema or Chronic Obstructive Pulmonary Disease
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
Prospective, 2-arm, randomised (2:1), multicentre, open-label clinical trial in patients with severe emphysema. The intervention arm will be treated with Bronchoscopic lung volume reduction in severe emphysema using…
- Trial name
- NCT05717192
- Testing
- InterVapor®-System
- Where
- 12 sites in Germany
- Volunteers
- 224 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Chronic Graft Versus Host Disease
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and…
- Trial name
- NCT04944043
- Testing
- TQ05105 Tablet
- Where
- 12 sites in China
- Volunteers
- 45 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease, Hypercapnic Respiratory Failure
Non-invasive Positive Pressure (NPPV ) for Severe Stable Chronic Obstructive Pulmonary Disease
Assessment of the effect and safety of noninvasive positive pressure ventilation for severe stable chronic obstructive pulmonary disease
- Trial name
- NCT02499718
- Testing
- BiPAP mode
- Where
- China
- Volunteers
- 368 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the…
- Trial name
- AERIFY-1 (NCT04701983)
- Testing
- Itepekimab SAR440340
- Where
- 232 sites in United States, Argentina and 19 more
- Volunteers
- 1,127 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD
Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise…
- Trial name
- NCT02182856
- Testing
- Ipratropium bromide 500 µg/salbutamol sulphate 3 mg, Ipratropium 500 µg, Salbutamol sulphate 3 mg
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT00361959
- Testing
- Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg
- Where
- 166 sites in Austria, Belgium and 18 more
- Volunteers
- 1,270 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04535986
- Testing
- Ensifentrine
- Where
- 122 sites in United States, Bulgaria and 10 more
- Volunteers
- 763 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
COPD
Early Palliative Care for Patients With Severe and Very Severe COPD: a Randomised Study
Chronic obstructive pulmonary disease (COPD) is a common and, despite existing treatment options, progressive lung disease. Patients with COPD often have only limited access to palliative care.
- Trial name
- NCT02223780
- Testing
- early palliative care
- Where
- Switzerland
- Volunteers
- 51 people
- Sponsor
- University Hospital, Geneva
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Stem Cell Transplant Complications
KIR Sequencing and Typing for Allograft in Nancy
The use of haploidentical donors for aHSCT has greatly increased this past decade leading to a major paradigm shift: while finding 10/10 HLA-matched donors represented the prior difficulty for decades, the current problem is…
- Trial name
- KIR-STAN (NCT04882605)
- Testing
- MHC typing, KIR typing, Assessment of KIR-based prediction scores
- Volunteers
- 156 people
- Sponsor
- Central Hospital, Nancy, France